Beranda › Hemofilia B › Michigan
Uji klinis Hemofilia B di Michigan
6 studi untuk Hemofilia B mencari peserta di lokasi di Michigan.
Kota di Michigan
Teks studi resmi (Bahasa Inggris)
Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B
- University of Michigan Medical Center, Ann Arbor
Menerima pesertaFase 3
138 Months – 206 Months · Pria · Diperbarui 16 Sep 2026 · NCT07080905A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B
- University of Michigan, Ann Arbor
Menerima pesertaFase 1/2
Usia 2 ke atas · Pria · Diperbarui 11 Sep 2026 · NCT06379789Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs)
- University of Michigan, Ann Arbor
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 27 Agu 2026 · NCT06003387ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
- Central Michigan Children's Hospital of Michigan, Detroit
- Henry Ford Health System Bleeding and Thrombosis Treatment Center, Detroit
Menerima pesertaStudi observasional
Semua usia · Semua jenis kelamin · Diperbarui 17 Agu 2026 · NCT04398628A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency)
- University of Michigan Hospitals - Michigan Medicine, Ann Arbor
Menerima pesertaFase 1Sukarelawan sehat diterima
Usia 18 hingga 60 · Semua jenis kelamin · Diperbarui 2 Jul 2026 · NCT06349473SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors
- Children's Hospital of Michigan, Detroit
- Henry Ford Health System, Detroit
- MSU Center for Bleeding and Clotting Disorders, Lansing
Menerima pesertaFase 4
Usia 12 hingga 100 · Semua jenis kelamin · Diperbarui 12 Jan 2026 · NCT04647227Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.